Archives of Neuroscience

Published by: Kowsar

Effect of Saffron (Crocus sativus L.) as an Add-On Therapy to Sertraline in Mild to Moderate Generalized Anxiety Disorder: A Double Blind Randomized Controlled Trial

Nasibe Jafarnia 1 , Zeinab Ghorbani 2 , 3 , Morteza Nokhostin 4 , Azadeh Manayi 5 , Saeedeh Nourimajd 1 and Soodeh Razeghi Jahromi 1 , *
Authors Information
1 Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
2 School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, IR Iran
3 Headache Department, Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, IR Iran
4 Psychiatry Department, Shahid Ansari Hospital, Guilan University of Medical Sciences, Rasht, Iran
5 Medicinal Plants Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, IR Iran
Article information
  • Archives of Neuroscience: October 2017, 4 (4); e14332
  • Published Online: October 14, 2017
  • Article Type: Research Article
  • Received: May 30, 2017
  • Revised: August 11, 2017
  • Accepted: September 2, 2017
  • DOI: 10.5812/archneurosci.14332

To Cite: Jafarnia N, Ghorbani Z, Nokhostin M, Manayi A, Nourimajd S, et al. Effect of Saffron (Crocus sativus L.) as an Add-On Therapy to Sertraline in Mild to Moderate Generalized Anxiety Disorder: A Double Blind Randomized Controlled Trial, Arch Neurosci. 2017 ; 4(4):e14332. doi: 10.5812/archneurosci.14332.

Abstract
Copyright © 2017, Archives of Neuroscience. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
Acknowledgements
Footnotes
References
  • 1. Bandelow B, Boerner JR, Kasper S, Linden M, Wittchen HU, Moller HJ. The diagnosis and treatment of generalized anxiety disorder. Dtsch Arztebl Int. 2013; 110(17): 300-9[DOI][PubMed]
  • 2. Nainian M, SHaeery M, SHarifi M, Hadiean M. Reliability and validity of the short scale Anxiety Disorder. Clin Psy Pers Shahed Univ. 2011; 4: 41-50
  • 3. Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006; 166(10): 1092-7[DOI][PubMed]
  • 4. Ahmadvand A, Sepehrmanesh Z, Ghoreishi FS, Afshinmajd S. Prevalence of psychiatric disorders in the general population of Kashan, Iran. Arch Iran Med. 2012; 15(4): 205-9[PubMed]
  • 5. Hoehn-Saric R. Characteristics of chronic anxiety patients. Anxiety: New research and changing concepts. 1981;
  • 6. Levitan MN, Papelbaum M, Nardi AE. Profile of agomelatine and its potential in the treatment of generalized anxiety disorder. Neuropsychiatr Dis Treat. 2015; 11: 1149-55[DOI][PubMed]
  • 7. Kianbakht S. A systematic review on pharmacology of saffron and its active constituents. J Med Plants. 2008; 4(28): 1-27
  • 8. Shahmansouri N, Farokhnia M, Abbasi SH, Kassaian SE, Noorbala Tafti AA, Gougol A, et al. A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patients. J Affect Disord. 2014; 155: 216-22[DOI][PubMed]
  • 9. Rahaiee S, Moini S, Hashemi M, Shojaosadati SA. Evaluation of antioxidant activities of bioactive compounds and various extracts obtained from saffron (Crocus sativus L.): a review. J Food Sci Technol. 2015; 52(4): 1881-8[DOI][PubMed]
  • 10. Hausenblas HA, Heekin K, Mutchie HL, Anton S. A systematic review of randomized controlled trials examining the effectiveness of saffron (Crocus sativus L.) on psychological and behavioral outcomes. J Integr Med. 2015; 13(4): 231-40[DOI][PubMed]
  • 11. Akhondzadeh S, Fallah-Pour H, Afkham K, Jamshidi AH, Khalighi-Cigaroudi F. Comparison of Crocus sativus L. and imipramine in the treatment of mild to moderate depression: a pilot double-blind randomized trial [ISRCTN45683816]. BMC Complement Altern Med. 2004; 4: 12[DOI][PubMed]
  • 12. Akhondzadeh S, Tahmacebi-Pour N, Noorbala AA, Amini H, Fallah-Pour H, Jamshidi AH, et al. Crocus sativus L. in the treatment of mild to moderate depression: a double-blind, randomized and placebo-controlled trial. Phytother Res. 2005; 19(2): 148-51[DOI][PubMed]
  • 13. Akhondzadeh Basti A, Moshiri E, Noorbala AA, Jamshidi AH, Abbasi SH, Akhondzadeh S. Comparison of petal of Crocus sativus L. and fluoxetine in the treatment of depressed outpatients: a pilot double-blind randomized trial. Prog Neuropsychopharmacol Biol Psychiatry. 2007; 31(2): 439-42[DOI][PubMed]
  • 14. Hosseinzadeh H, Karimi G, Nyapvr M. Comparative effects of antidepressant saffron extract and its active ingredients, crocin and safranal in mice. J Med Plants. 2004; 3(11): 48-58
  • 15. Moosavi SM, Ahmadi M, Amini M, Vazirzadeh B. The Effects of 40 and 80 mg Hydro-alcoholic Extract of Crocus Sativus in the Treatment of Mild to Moderate Depression. J Mazandaran Univ Med Sci. 2014; 24(113): 48-53
  • 16. Noorbala AA, Akhondzadeh S, Tahmacebi-Pour N, Jamshidi AH. Hydro-alcoholic extract of Crocus sativus L. versus fluoxetine in the treatment of mild to moderate depression: a double-blind, randomized pilot trial. J Ethnopharmacol. 2005; 97(2): 281-4[DOI][PubMed]
  • 17. Pitsikas N, Boultadakis A, Georgiadou G, Tarantilis PA, Sakellaridis N. Effects of the active constituents of Crocus sativus L., crocins, in an animal model of anxiety. Phytomedicine. 2008; 15(12): 1135-9[DOI][PubMed]
  • 18. Hosseinzadeh H, Noraei NB. Anxiolytic and hypnotic effect of Crocus sativus aqueous extract and its constituents, crocin and safranal, in mice. Phytother Res. 2009; 23(6): 768-74[DOI][PubMed]
  • 19. Diagnostic and statistical manual of mental disorders (DSM-5®). 2013;
  • 20. Hamilton M. Diagnosis and Rating of Anxiety. Br J Psychiat Spec. 1969; 3: 76-9
  • 21. Georgiadou G, Tarantilis PA, Pitsikas N. Effects of the active constituents of Crocus Sativus L., crocins, in an animal model of obsessive-compulsive disorder. Neurosci Lett. 2012; 528(1): 27-30[DOI][PubMed]
  • 22. Halataei BA, Khosravi M, Arbabian S, Sahraei H, Golmanesh L, Zardooz H, et al. Saffron (Crocus sativus) aqueous extract and its constituent crocin reduces stress-induced anorexia in mice. Phytother Res. 2011; 25(12): 1833-8[DOI][PubMed]
  • 23. Borkovec TD, Newman MG, Castonguay LG. Cognitive-behavioral therapy for generalized anxiety disorder with integrations from interpersonal and experiential therapies. CNS Spectr. 2003; 8(5): 382-9[PubMed]
  • 24. Pitsikas N. Constituents of Saffron (Crocus sativus L.) as Potential Candidates for the Treatment of Anxiety Disorders and Schizophrenia. Molecules. 2016; 21(3): 303[DOI][PubMed]
  • 25. Ettehadi H, Mojabi SN, Ranjbaran M, Shams J, Sahraei H, Hedayati M, et al. Aqueous Extract of Saffron (<i>Crocus sativus</i>) Increases Brain Dopamine and Glutamate Concentrations in Rats. J Behav Brain Sci. 2013; 3(3): 315-9[DOI]
  • 26. Zarrindast MR, Khakpai F. The Modulatory Role of Dopamine in Anxiety-like Behavior. Arch Iran Med. 2015; 18(9): 591-603[PubMed]
  • 27. Nikolaus S, Antke C, Beu M, Muller HW. Cortical GABA, striatal dopamine and midbrain serotonin as the key players in compulsive and anxiety disorders--results from in vivo imaging studies. Rev Neurosci. 2010; 21(2): 119-39[PubMed]
  • 28. Mazidi M, Shemshian M, Mousavi SH, Norouzy A, Kermani T, Moghiman T, et al. A double-blind, randomized and placebo-controlled trial of Saffron (Crocus sativus L.) in the treatment of anxiety and depression. J Complement Integr Med. 2016; 13(2): 195-9[DOI][PubMed]
  • 29. Sarris J, Panossian A, Schweitzer I, Stough C, Scholey A. Herbal medicine for depression, anxiety and insomnia: a review of psychopharmacology and clinical evidence. Eur Neuropsychopharmacol. 2011; 21(12): 841-60[DOI][PubMed]
  • 30. Fava M, Judge R, Hoog SL, Nilsson ME, Koke SC. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry. 2000; 61(11): 863-7[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments